For instance, a patient with coronary disease, genotyped for CYP2C19 (and all the other genes) prior to the surgery, could eventually be receiving medical care in their primary health center; in addition, this patient could be receiving simvastatin to control cholesterol blood levels; providing the physician at the primary health center with a set of clinically relevant pharmacogenetic information (in this case, SLCO1B1 phenotype would be the relevant biomarker) would signify better management of this patient. The gene discussed is SLCO1B1; the disease is coronary artery disorder.